Synklino raises 30 million euros for cytomegalovirus candidate

Danish biotech Synklino has completed a Series A fundraising of 29.8 million euros ($31.8 million).

Synklino, a spinout from the University of Copenhagen and the Technical University of Denmark, is developing breakthrough drugs for the treatment of chronic viral infections.

With the capital raised, Synklino will advance its drug candidate SYN002 for the treatment of cytomegalovirus (CMV), into both ex vivo and in vivo Phase I trials and generate safety and efficacy data to establishing a solid foundation for expanding the firm’s pipeline, and widening the strategic options for further value creation.